Bruker Corporation ( BRKR )  reported preliminary revenue Friday for the first quarter that ended March 31, 2025, of $795 million to $800 million compared to a consensus of $758.85 million.

The company’s sales reflect around 10-11% year-over-year increase from $721.70 million.

Bruker Corporation ( BRKR ) is an American manufacturer of scientific instruments for molecular and materials research and industrial and applied analysis.

This estimated range implies a reported revenue growth of approximately 10% year over year, with low double-digit percentage constant exchange rate revenue growth.

Bruker ( BRKR ) estimates adjusted organic revenue growth in the first quarter to be in the low single-digit percentages, with mid-single-digit percentage organic revenue growth in the Bruker Scientific Instrument (BSI) segment and a high-teens percentage organic revenue decline in the Bruker Energy & Supercon Technologies (BEST) segment, net of intercompany eliminations.

Concurrently, at the ESCMID Global 2025 conference, Bruker’s Microbiology and Infection Diagnostics division is announcing the expansion of its microbiology solutions into Next-Generation Sequencing (NGS) applications, with new, research-use-only NGS-based solutions in epidemiology and hospital-acquired infection (HAI) tracing.

On Friday, Bruker ( BRKR ) entered into a strategic collaboration with Ridom GmbH, based in Muenster, Germany, for NGS bioinformatics applications in microbiology and infectious disease testing.

Ridom’s NGS bioinformatics software SeqSphere+ is designed for genomic bacterial strain differentiation, multilocus sequence typing (MLST), core genome MLST (cgMLST), phylogenetic analysis, and real-time clonal and plasmid transmission detection. 

SeqSphere+ can handle data from various NGS instrument platforms. Financial details of the investment were not disclosed.

In October 2024, Bruker ( BRKR ) acquired Dynamic Biosensors GmbH, a biosensor development company based in Munich, Germany.

The acquisition strengthened Bruker’s biophysical portfolio for analyzing molecular interactions and kinetics.

Price Action: BRKR’s stock was up 2.47% at $39.01 during the premarket session on Friday.

Read Next:

BlackRock’s Bold Quarter: EPS Tops, $11.6 Trillion AUM, $84 Billion Inflows Power Growth